Rhumbline Advisers raised its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 96.4% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 22,953 shares of the biotechnology company’s stock after acquiring an additional 11,266 shares during the period. Rhumbline Advisers owned approximately 0.09% of Aclaris Therapeutics worth $622,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. Rice Hall James & Associates LLC grew its stake in Aclaris Therapeutics by 23.1% in the second quarter. Rice Hall James & Associates LLC now owns 42,869 shares of the biotechnology company’s stock valued at $1,163,000 after acquiring an additional 8,042 shares during the period. C WorldWide Group Holding A S grew its stake in Aclaris Therapeutics by 18.5% in the second quarter. C WorldWide Group Holding A S now owns 96,600 shares of the biotechnology company’s stock valued at $2,620,000 after acquiring an additional 15,100 shares during the period. Schwab Charles Investment Management Inc. grew its stake in Aclaris Therapeutics by 40.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock valued at $1,676,000 after acquiring an additional 17,804 shares during the period. TD Asset Management Inc. grew its stake in Aclaris Therapeutics by 15.6% in the second quarter. TD Asset Management Inc. now owns 17,100 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 2,304 shares during the period. Finally, Sei Investments Co. grew its stake in Aclaris Therapeutics by 2,828.4% in the second quarter. Sei Investments Co. now owns 11,040 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 10,663 shares during the period. 95.79% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on ACRS shares. Jefferies Group LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, June 28th. BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. ValuEngine cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 6th. Finally, Guggenheim reaffirmed a “buy” rating and set a $40.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $40.00.

In related news, Director Andrew N. Schiff acquired 108,601 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The stock was bought at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 16.30% of the stock is owned by company insiders.

WARNING: “Rhumbline Advisers Increases Holdings in Aclaris Therapeutics, Inc. (ACRS)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/rhumbline-advisers-increases-holdings-in-aclaris-therapeutics-inc-acrs/1600076.html.

Aclaris Therapeutics, Inc. (NASDAQ ACRS) opened at 25.81 on Friday. Aclaris Therapeutics, Inc. has a 12 month low of $20.15 and a 12 month high of $33.25. The stock’s market cap is $690.06 million. The company’s 50 day moving average price is $25.99 and its 200 day moving average price is $27.57.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.12. Equities analysts forecast that Aclaris Therapeutics, Inc. will post ($3.10) EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.